Diffuse Astrocytic and Oligodendroglial Tumors in Adults
Key Points
Key Points
- Each year, more than 15,000 people in the United States are newly diagnosed with diffuse astrocytic and oligodendroglial tumors, including glioblastoma.
- Recently, several systemic agents and a device have demonstrated improvements in survival when added to surgical and radiation therapies.
- Genetic alterations, specifically Isocitrate Dehydrogenase 1 and 2 (IDH1 and IDH2), have become critical classification and prognostic biomarkers.
Treatment
Treatment
...mutant Astrocytic and Oligodendro...
...dendroglioma, IDH-mutant, 1p/19q co-deleted, C...
...commendation 1.1People with oligodendroglio...
...mide is a reasonable alternative to PCV when tox...
...1.2Within the group of people with ol...
Oligodendroglioma, IDH-mutant, 1p/19q co-delete...
...commendation 1.3People with oligodendrogl...
...zolomide is a reasonable alternative t...
...a, IDH-mutant, 1p/19q non-codeleted, CNS WH...
...ommendation 1.4People with astrocytoma, ID...
...endation 1.5In astrocytoma, IDH-mutant, 1p/...
...ocytoma, IDH-mutant, 1p/19q non-codeleted, CNS WH...
...ndation 1.6People with astrocytoma, IDH-mutant, 1...
...DH-mutant, CNS WHO grade 4 (former ID...
....7People with astrocytoma, IDH-mutant C...
...lioblastoma and Other IDH-wildtype Diffuse Glioma
...ommendation 2.1People with astrocytomas, IDH-wil...
...on 2.2Concurrent temozolomide and radiation ther...
Recommendation 2.3Six months of ad...
Recommendation 2.4Alternating electric field thera...
Recommendation 2.5Bevacizumab is NOT recomme...
...2.6In people with glioblastoma, IDH-wildtype, CNS...
...endation 2.7In people with glioblastoma...
...ecommendation 2.8No recommendation for or ag...
...with recurrent glioblastoma should be referred...
....9No recommendation for or against any thera...
People with diffuse midline glioma should be r...
...able 1. Reasonable Doses and Schedules by...